{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:17:33Z","timestamp":1789395453037,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006365","name":"Universidad de Cantabria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006365","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00198-026-07854-5","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:21:08Z","timestamp":1769098868000},"page":"637-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypercalcemia after denosumab discontinuation in patients with osteoporosis: a systematic review and case report"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4804-5641","authenticated-orcid":false,"given":"Javier Queipo","family":"Men\u00e9ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lex","family":"Garc\u00eda Tellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pardo Lleidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Hern\u00e1ndez Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"5","key":"7854_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.mcna.2020.06.004","volume":"104","author":"CB Johnston","year":"2020","unstructured":"Johnston CB, Dagar M (2020) Osteoporosis in older adults. Med Clin North Am 104(5):873\u2013884. https:\/\/doi.org\/10.1016\/j.mcna.2020.06.004","journal-title":"Med Clin North Am"},{"key":"7854_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1133828","volume":"13","author":"J Lu","year":"2023","unstructured":"Lu J, Hu D, Zhang Y, Ma C, Shen L, Shuai B (2023) Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Front Oncol 13:1133828. https:\/\/doi.org\/10.3389\/fonc.2023.1133828","journal-title":"Front Oncol"},{"issue":"5","key":"7854_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/ijcp.12022","volume":"67","author":"DA Hanley","year":"2013","unstructured":"Hanley DA, Adachi JD, Brown JP (2013) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 67(5):556\u2013565. https:\/\/doi.org\/10.1111\/ijcp.12022","journal-title":"Int J Clin Pract"},{"issue":"1","key":"7854_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4321\/S1889-836X2022000100003","volume":"14","author":"JA Riancho","year":"2022","unstructured":"Riancho JA, Peris P, Gonz\u00e1lez-Mac\u00edas J, P\u00e9rez-Castrill\u00f3n JL (2022) Clinical practice guidelines for postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update). Rev Osteoporos Metab Miner 14(1):13\u201333. https:\/\/doi.org\/10.4321\/S1889-836X2022000100003","journal-title":"Rev Osteoporos Metab Miner"},{"key":"7854_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"issue":"4","key":"7854_CR6","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC et al (2011) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7854_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","volume":"21","author":"AS S\u00f8lling","year":"2023","unstructured":"S\u00f8lling AS, Tsourdi E, Harsl\u00f8f T, Langdahl BL (2023) Denosumab discontinuation. Curr Osteoporos Rep 21(1):95\u2013103. https:\/\/doi.org\/10.1007\/s11914-022-00771-6","journal-title":"Curr Osteoporos Rep"},{"issue":"12","key":"7854_CR8","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00198-020-05676-7","volume":"31","author":"C Camponovo","year":"2020","unstructured":"Camponovo C, Aubry-Rozier B, Lamy O, Gonzalez Rodriguez E (2020) Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. Osteoporos Int 31(12):2485\u20132491. https:\/\/doi.org\/10.1007\/s00198-020-05676-7","journal-title":"Osteoporos Int"},{"issue":"7","key":"7854_CR9","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","volume":"27","author":"AS Koldkj\u00e6r-S\u00f8lling","year":"2016","unstructured":"Koldkj\u00e6r-S\u00f8lling AS, Harsl\u00f8f T, Kaal A, Rejnmark L, Langdahl B (2016) Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int 27(7):2383\u20132386. https:\/\/doi.org\/10.1007\/s00198-016-3535-5","journal-title":"Osteoporos Int"},{"issue":"1","key":"7854_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02401-0","volume":"14","author":"Y Maugars","year":"2020","unstructured":"Maugars Y, Guillot P, Gl\u00e9marec J, Berthelot JM, Le Goff B, Darrieutort-Laffite C (2020) Long-term follow-up after denosumab treatment for osteoporosis: rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report. J Med Case Rep 14(1):130. https:\/\/doi.org\/10.1186\/s13256-020-02401-0","journal-title":"J Med Case Rep"},{"key":"7854_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"3","key":"7854_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.20960\/RevOsteoporosMetabMiner.00045","volume":"16","author":"\u00c1 P\u00e9rez-Mart\u00edn","year":"2024","unstructured":"P\u00e9rez-Mart\u00edn \u00c1, L\u00f3pez-Lanza JR, Bustamante-Odriozola J, Guti\u00e9rrez-Revilla JI, Ag\u00fceros-Fern\u00e1ndez MJ, P\u00e9rez-Guijarro A, Olmos JM, Mart\u00ednez-Taboada V, Hern\u00e1ndez JL (2024) Adherence to denosumab during the COVID-19 pandemic. Rev Osteoporos Metab Miner 16(3):71\u201378. https:\/\/doi.org\/10.20960\/RevOsteoporosMetabMiner.00045","journal-title":"Rev Osteoporos Metab Miner"},{"issue":"8","key":"7854_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"issue":"2","key":"7854_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: post hoc analysis of the FREEDOM trial and its Extension. J Bone Miner Res 33(2):190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337","journal-title":"J Bone Miner Res"},{"issue":"10","key":"7854_CR15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.4045","volume":"25","author":"AL Huynh","year":"2016","unstructured":"Huynh AL, Baker ST, Stewardson AJ, Johnson DF (2016) Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf 25(10):1274\u20131278. https:\/\/doi.org\/10.1002\/pds.4045","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7854_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101148","volume":"15","author":"T Horiuchi","year":"2021","unstructured":"Horiuchi T, Shiba N, Ogata N (2021) Hypercalcemia after denosumab discontinuation: a systematic review. Bone Rep 15:101148. https:\/\/doi.org\/10.1016\/j.bonr.2021.101148","journal-title":"Bone Rep"},{"issue":"1\u20132","key":"7854_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cca.2009.08.020","volume":"409","author":"J Mart\u00ednez","year":"2009","unstructured":"Mart\u00ednez J, Olmos JM, Hern\u00e1ndez JL, Pinedo G, Llorca J, Obreg\u00f3n E et al (2009) Bone turnover markers in Spanish postmenopausal women: the Camargo cohort study. Clin Chim Acta 409(1\u20132):70\u201374. https:\/\/doi.org\/10.1016\/j.cca.2009.08.020","journal-title":"Clin Chim Acta"},{"issue":"9","key":"7854_CR18","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt P, Faouzi M, Buclin T, Lamy O, Swiss Denosumab Study Group (2021) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36(9):1717\u20131728. https:\/\/doi.org\/10.1002\/jbmr.4335","journal-title":"J Bone Miner Res"},{"issue":"5","key":"7854_CR19","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07854-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:36:56Z","timestamp":1776245816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-07854-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7854"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07854-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}